Inutility of IMP3 Marker in Differentiating Hodgkin Lymphoma from Large Cell Lymphoma
Background: Hodgkin’s lymphoma is one of the most commonly diagnosed lymphomas in Western society. Today Reed-Sternberg cells are identified by positive staining of several biomarkers. The IMP3 (insulin-like growth factor II m-RNA-binding protein 3) marker is a member of the insulin-like growth fac...
Main Authors: | Ali Zare Mehrjerdi, Mahdie Ahmadi |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2020-08-01
|
Series: | Basic & Clinical Cancer Research |
Subjects: | |
Online Access: | https://bccr.tums.ac.ir/index.php/bccrj/article/view/351 |
Similar Items
-
Diagnostic importance of immunohistochemical markers expression in differential diagnostics of classical Hodgkin Lymphoma
by: Gurtovyy V.A.
Published: (2012-01-01) -
Functional aspects of the CD30 gene in Hodgkin’s lymphoma and anaplastic large cell lymphoma
by: Desiree S. Ho, et al.
Published: (2011-12-01) -
Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01) -
CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
by: Dody Ranuhardy, et al.
Published: (2018-06-01) -
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
by: Donato EM, et al.
Published: (2018-08-01)